Authors:
Alvian Mohamad Yapanto, Lilian Batubara, Wening Sari
Addresses:
Medical Education Study Program, Faculty of Medicine, YARSI University, Cempaka Putih, Jakarta, Indonesia. Department of Pharmacology, Faculty of Medicine, YARSI University, Cempaka Putih, Jakarta, Indonesia.
UTI is one of the most prevalent infections in Indonesia, with a prevalence rate of 15%. Antibiotic resistance complicates UTI treatment. Assessing antibiotic use can help prevent the development of antibiotic resistance. This study analyses the characteristics and profile of UTI patients at Dr Drajat Prawiranegara in 2022 and evaluates antibiotic use based on Gyssens' guidelines. For this investigation, 50 medical records were consecutively sampled. This study reported that 46% of patients were male and 64% female. Patients were 0-5 years (6%), 12-16 years (4%), 17-25 years (12%), 26-35 years (28%), 36-45 years (12%), 46-55 years (16%), 56-65 years (10%), and over 65 years (10%) old. Medical records showed that ceftriaxone (43%), levofloxacin (31%), cefotaxime (16%), cefoperazone (4.1%), and cefoperazone-sulbactam (4.1%) were the most commonly administered antibiotics. All patients received IV antibiotics. The Gyssens technique found that 74% of patients used antibiotics rationally. The remaining 26% use antibiotics irrationally, with differences within each category. This study found that most UTI patients at RSUD Dr Drajat Prawiranegara received medications logically. However, age, gender, medical history, and health problems can impact antibiotic use. For more representative and thorough results, bigger sample sizes and multidisciplinary teams are recommended.
Keywords: Urinary Tract Infection Antibiotics; Quality of Using Antibiotics; Gyssens Method; Infectious Diseases; Antibiotic Resistance; Health Conditions; Urinary Tract Infection patients.
Received on: 18/09/2024, Revised on: 30/11/2024, Accepted on: 14/01/2025, Published on: 05/06/2025
DOI: 10.69888/FTSHSL.2025.000460
FMDB Transactions on Sustainable Health Science Letters, 2025 Vol. 3 No. 2, Pages: 80-91